T cell engagers emerge as a compelling therapeutic modality. New review from Baeuerle, Grieshaber-Bouyer, Sauer, and Michaelson: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #TcellEngagers

Athanasia Dasargyri will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

Hypoxia-driven MUC16/CA125 downregulation, #VEGF secretion, and #EMT emerge as #tumor-intrinsic mechanisms of resistance to MUC16-directed bispecific #TcellEngagers in #OvarianCancer, and VEGF blockade restores #cytotoxicity. @harvardmed.bsky.social

#STTT: doi.org/10.1038/s413...

#TcellEngagers (#TCEs) are engineered to redirect the body’s #Tcells toward disease. Their versatility, expanding target range, and growing clinical impact are redefining immune-based therapy. In a new review, Baeuerle et al. describe why they’re rising so quickly.: rupress.org/jem/article/...

Heading to Milan for BIO-Europe Spring! Our Chief Business Officer @Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatment—plus what’s ahead for our innovative M-gager® platform. Let’s connect! #BIOEuropeSpring
#TCellEngagers

This week’s deal flow sends a clean signal: capital is not retreating from innovation—it is becoming more selective about where technical risk is taken and how it is transferred.
#BCIC #BiotechInvesting #AntibodyTherapeutics
#TCellEngagers #BispecificAntibodies #ADC
#GeneTherapy #RareDisease

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.
academic.oup.com/abt/article/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #tcellengagers #cd3

Assessing the safety of TCEs remains a critical challenge.
At AACR 2026, researchers from Seattle Children’s showed how humanized CD3 mouse models can differentiate the in vivo safety profiles of CD3 binders
🔎 Learn more: bit.ly/4uBlDZA
#ImmunoOncology #TCellEngagers #PreclinicalResearch

🔬 How do you reliably assess T cell engager efficacy and safety before moving to the clinic?
Join our live webinar
📢 Advancing T Cell Engagers: Addressing Key Efficacy & Safety Challenges
👉 Register: bit.ly/3RPIr9n
#ImmunoOncology #PreclinicalResearch #TCellEngagers #Webinar

How do you better assess the safety of bispecific TCEs?-
At #AACR2026, data from Seattle Children’s shows a PD-L1:CD3 TCE with strong anti-tumor activity and a favorable safety profile using genOway’s humanized mouse model. bit.ly/4wKuM3r

#ImmunoOncology #TCellEngagers #HumanizedMouseModels

Sanofi is making a bigger bet on next-generation immune cell redirection in autoimmune disease.

www.linkedin.com/posts/boston...

Wonderful opportunity to #share & #discuss emerging role of #TCellEngagers #BiTEs in Mx of #SCLC 🫁 w/ our Malaysian 🇲🇾 colleagues during #LCS2025.

Small group discussions (esp. over a meal! 😋) are always very interactive for experience sharing.

#LCSM @APCLC_2023 @apoddc @cuhkmedicine.bsky.social

#JazzPharma has made a big move into #Tcellengagers (TCEs) for #cancer, via an #alliance with #AbCellera that spans up to five candidates that could each generate milestones of up to $792 million.

Athanasia Dasargyri of CDR-Life will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

CDR-Life is at #BIOEquityEurope! CEO Christian Leisner is sharing how our M-gager® T cell engagers are advancing solid tumor & autoimmune therapies. Meet in person or join virtual partnering next week to connect. #TCellEngagers

#TcellEngagers (#TCEs) are engineered to redirect the body’s #Tcells toward disease. Their versatility, expanding target range, and growing clinical impact are redefining immune-based therapy. In a @jem.org review, Baeuerle et al. describe why they’re rising so quickly.: rupress.org/jem/article/...